Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 218

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 218
---
 The terms of the Convertible Notes, however, permit Yorkville to increase         
 to a higher percentage than 4.99% the maximum percentage beneficial ownership of our common stock for purposes of determining the Beneficial  
 Ownership Limitation applicable under the Convertible Notes by delivering to us written notice thereof specifying such higher percentage,     
 which increased beneficial ownership limitation will not become effective until the 65th day after delivery of such written                   
 notice to the Company. Unlike the Convertible Notes, however, the SEPA does not permit Yorkville to modify or waive the 4.99% Beneficial      
 Ownership Limitation for purposes of limitations on the amount of Advance Shares that we may issue and sell to Yorkville under the SEPA.      |

| (2) | Applicable percentage ownership is based                                      
 on 34,426,355 shares of our common stock outstanding as of November 25, 2025. |

| (3) | Assumes the sale of all shares of our common stock being offered for resale pursuant to this prospectus. |

| (4) | Yorkville is a fund managed by Yorkville Advisors Global, LP (“Yorkville LP”). Yorkville Advisors                             
 Global II, LLC (“Yorkville LLC”) is the general partner of Yorkville LP. All investment decisions for Yorkville are made by   
 Yorkville LLC’s President and managing member, Mr. Mark Angelo. The business address of Yorkville is 1012 Springfield Avenue, 
 Mountainside, NJ 07092.                                                                                                       |

<div align='center'>DESCRIPTION OF SECURITIES</div>

The following description of our capital stock is based upon our Certificate of Incorporation, as amended, our amended and restated bylaws, as amended, and applicable provisions of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended, and our amended and restated bylaws, copies of which are filed with the SEC as exhibits to the Registration Statement of which this prospectus is a part.

Authorized Capital Stock

As of November 25,
2025, our authorized capital stock consists of (i) 125,000,000 shares of common stock, par value $0.0001 per share, and (ii) 5,000,000
shares of preferred stock, par value $0.0001 per share. As of November 25, 2025, we had 34,426,355 shares of common